Best Practice and Research. Clinical Haematology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Off the shelf T cell therapies for hematologic malignancies
Publication date: Available online 28 March 2018 Source:Best Practice & Research Clinical Haematology Author(s): Bruce J. McCreedy, Vladimir V. Senyukov, Kim T. Nguyen Adoptive transfer of autologous CAR-T cells can induce durable remissions in patients with relapsed/refractory hematologic malignancies. However, multiple challenges exist for manufacturing CAR-T cells from patients with advanced disease including inability to manufacture a product, disease progression or death while waiting for the CAR-T product to be available, and heterogeneity among autologous CAR-T products that contributes to unpredictable...
Source: Best Practice and Research Clinical Haematology - April 2, 2018 Category: Hematology Source Type: research

Toxicities associated with immunotherapies for hematologic malignancies
Publication date: Available online 28 March 2018 Source:Best Practice & Research Clinical Haematology Author(s): Mark B. Leick, Marcela V. Maus Immunotherapy has generated tremendous hope for patients with cancer that is refractory to standard approaches. Hematologic malignancies have taken the lead in harnessing the most recent advances in cell-based immunotherapies, such as CAR T cells, and some patients have achieved durable remissions. However, these T-cell-engaging therapies are associated with a new set of toxicities which need to be managed by caretakers, oncologists, nurses, and healthcare staff. In thi...
Source: Best Practice and Research Clinical Haematology - April 2, 2018 Category: Hematology Source Type: research

Novel therapies for relapsed/refractory mantle cell lymphoma
Publication date: Available online 2 November 2017 Source:Best Practice & Research Clinical Haematology Author(s): Puja C. Arora, Craig A. Portell Mantle cell lymphoma is an aggressive Non-Hodgkin's lymphoma that is considered incurable with standard therapies. Most patients treated with frontline immunochemotherapy relapse within a few years and do not usually respond to salvage chemotherapy. Persistent activation of the B-cell receptor pathway is critical to the pathogenesis of mantle cell lymphoma. Inhibition of Bruton's tyrosine kinase, an essential B-cell receptor pathway component with ibrutinib has shown...
Source: Best Practice and Research Clinical Haematology - December 16, 2017 Category: Hematology Source Type: research

Optimal management of the young patient CLL patient
Publication date: Available online 2 November 2017 Source:Best Practice & Research Clinical Haematology Author(s): John N. Allan, Richard R. Furman The emergence of targeted therapy for patients with chronic lymphocytic leukemia (CLL) has permanently altered the therapeutic landscape. In both upfront and relapsed settings, safe and effective oral kinase inhibitors are available which rival the responses and durability seen with standard chemo immunotherapy regimens. In 2016, ibrutinib was granted Federal Drug Administration approval for first-line therapy in patients with CLL. While its role as initial therapy ...
Source: Best Practice and Research Clinical Haematology - December 16, 2017 Category: Hematology Source Type: research

Risk stratification in follicular lymphoma
Publication date: Available online 15 November 2017 Source:Best Practice & Research Clinical Haematology Author(s): Carla Casulo Advances in the understanding of FL biology, molecular characteristics and clinical risk factors are further highlighting the heterogeneity of this disease. Historically used prognostic factors were broadly based on clinical and laboratory features at the time of diagnosis. However novel prognostic factors are emerging that can be studied at the time of diagnosis, and relapse, and use a variety of tools including gene alterations and diagnostic imaging. These novel discoveries are bein...
Source: Best Practice and Research Clinical Haematology - December 16, 2017 Category: Hematology Source Type: research

Novel agents for relapsed and refractory follicular lymphoma
Publication date: Available online 16 November 2017 Source:Best Practice & Research Clinical Haematology Author(s): Chan Yoon Cheah, Nathan H. Fowler Follicular lymphoma is one of the most common non-Hodgkin's lymphomas. Although current frontline regimens are associated with high response rates, most patients still relapse. When progression is discovered, re-establishing the diagnosis and ruling out transformation in paramount. The outcomes following relapse have been improving due to the activity and increasing availability of novel agents with various mechanisms of action. Despite these advances, single agen...
Source: Best Practice and Research Clinical Haematology - December 16, 2017 Category: Hematology Source Type: research

Overview on the management of non-gastric MALT lymphomas
Publication date: Available online 14 November 2017 Source:Best Practice & Research Clinical Haematology Author(s): Irene Defrancesco, Luca Arcaini Extranodal marginal zone B-cell lymphomas (EMZLs) of the mucosa-associated lymphoid tissue (MALT) are indolent lymphomas which can present at any extranodal site. The most frequent localizations (other than stomach) are ocular adnexa, salivary gland, skin, lung and thyroid. Chronic inflammation and antigenic stimulation are a potential risk for the development of MALT lymphomas. While Helicobacter Pylori is known to be associated with gastric MALT lymphoma and antib...
Source: Best Practice and Research Clinical Haematology - November 15, 2017 Category: Hematology Source Type: research

The role of stem cell transplantation in follicular lymphoma
Publication date: Available online 3 November 2017 Source:Best Practice & Research Clinical Haematology Author(s): Georg Hess With the introduction of novel treatments paradigms to if or when to use transplantation strategies for patients with follicular lymphoma have changed substantially. Autologous transplantation has been intensively evaluated as consolidation after first induction treatment with positive effects, however the introduction of Rituximab led to comparable improvements and HDT has been moved to relapse treatment. In this indication HDT was frequently use already at first relapse, but now is domi...
Source: Best Practice and Research Clinical Haematology - November 10, 2017 Category: Hematology Source Type: research

Should rituximab replace splenectomy in the management of splenic marginal zone lymphoma?
Publication date: Available online 7 November 2017 Source:Best Practice & Research Clinical Haematology Author(s): Christina Kalpadakis, Gerassimos A. Pangalis, Maria K. Angelopoulou, Sotirios Sachanas, Theodoros P. Vassilakopoulos Background SMZL is a relatively rare low grade B-cell lymphoma, characterized usually by an indolent clinical behavior. Since there is no prospective randomized trials to establish the best treatment approach, decision on therapeutic management should be based on the available retrospective series. Based on these data, rituximab and splenectomy appear to be the most effective. Spl...
Source: Best Practice and Research Clinical Haematology - November 8, 2017 Category: Hematology Source Type: research

What is the optimal initial management of the younger mantle cell lymphoma patient?
Publication date: Available online 1 November 2017 Source:Best Practice & Research Clinical Haematology Author(s): Rory McCulloch, Simon Rule The last 20 years has seen considerable advances made in the management of younger patients with mantle cell lymphoma. The use of high dose cytarabine and rituximab in induction therapy, usually followed by autologous stem cell transplant consolidation, has become established practice and the median overall survival now exceeds 10 years. However, this high intensity upfront approach is not necessarily appropriate for all newly diagnosed patients. A minority exhibit diseas...
Source: Best Practice and Research Clinical Haematology - November 1, 2017 Category: Hematology Source Type: research

Management of untreated advanced stage follicular lymphoma: Role of patient discernment
Publication date: Available online 1 November 2017 Source:Best Practice & Research Clinical Haematology Author(s): Jayadev Manikkam Umakanthan, Mathew A. Lunning Follicular lymphoma is the most common indolent non-Hodgkin lymphoma. Advanced stage disease is common at diagnosis. The timing of treatment for follicular lymphoma is best approached by considering the combination of presence or absence of symptoms along with estimation of tumor burden. Upfront treatment strategies should take into initial presentation variables, pace of disease progression and goals of care after discussion with the patient. Treatmen...
Source: Best Practice and Research Clinical Haematology - November 1, 2017 Category: Hematology Source Type: research

What is the optimal management of older CLL patients?
Publication date: Available online 1 November 2017 Source:Best Practice & Research Clinical Haematology Author(s): Jennifer A. Woyach CLL is the most common leukemia in older adults with a median age at diagnosis of 71. Therefore, management of patients with this disease must take into account the older age of most patients and consequences of this in terms of functional status and organ function. This review will discuss the management of CLL with regards to observation prior to the initiation of therapy, functional status, and initial treatment. We will discuss criteria for the initiation of therapy, and how i...
Source: Best Practice and Research Clinical Haematology - November 1, 2017 Category: Hematology Source Type: research

Pathogenesis of follicular lymphoma
Publication date: Available online 1 November 2017 Source:Best Practice & Research Clinical Haematology Author(s): Tracy Lackraj, Rashmi Goswami, Robert Kridel Follicular lymphoma (FL) is presented as a germinal centre B-cell lymphoma that is characterized by an indolent clinical course, but remains – paradoxically – largely incurable to date. The last years have seen significant progress in our understanding of FL lymphomagenesis, which is a multi-step process beginning in the bone marrow with the hallmark t(14; 18)(q32; q21) translocation. The pathobiology of FL is complex and combines broad somatic chan...
Source: Best Practice and Research Clinical Haematology - November 1, 2017 Category: Hematology Source Type: research

Transformation of follicular lymphoma – Why does it happen and can it be prevented?
Publication date: Available online 1 November 2017 Source:Best Practice & Research Clinical Haematology Author(s): Brian K. Link Follicular lymphoma is a clinical disease with a multitude of presentations and behaviors. Although infrequent, transformation of follicular lymphoma to a more aggressive behaving subtype – prototypically diffuse large B-cell lymphoma – confers a substantially adverse prognosis. There is no consensus for optimal management after transformation is recognized. Historically considered a distinct clinical event, this review highlights the multiple subclinical transformational events th...
Source: Best Practice and Research Clinical Haematology - November 1, 2017 Category: Hematology Source Type: research

Mutational complexity in myelodysplasia
Publication date: Available online 25 October 2017 Source:Best Practice & Research Clinical Haematology Author(s): R. Coleman Lindsley Myelodysplastic syndromes are characterized by genetic and clinical heterogeneity. Some mutations are able to drive clonal hematopoiesis without causing clinical consequences, while other mutations may have significant impact, including the transformation to leukemia. This review aims to describe the pathogenesis of myelodysplastic syndromes (MDS) by focusing on 3 aspects: combinatorial genetic events, environmental factors, and inherited genetic conditions. (Source: Best Practic...
Source: Best Practice and Research Clinical Haematology - October 26, 2017 Category: Hematology Source Type: research